These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 10811138)

  • 1. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
    Miyake H; Nelson C; Rennie PS; Gleave ME
    Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.
    Miyake H; Nelson C; Rennie PS; Gleave ME
    Cancer Res; 2000 Jan; 60(1):170-6. PubMed ID: 10646870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
    Miyake H; Chi KN; Gleave ME
    Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.
    Miyake H; Pollak M; Gleave ME
    Cancer Res; 2000 Jun; 60(11):3058-64. PubMed ID: 10850457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
    Miyake H; Hara I; Kamidono S; Gleave ME
    Clin Cancer Res; 2001 Dec; 7(12):4245-52. PubMed ID: 11751526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression.
    Miyake H; Hara I; Kamidono S; Gleave ME; Eto H
    Oncol Rep; 2003; 10(2):469-73. PubMed ID: 12579291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
    Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
    Gleave ME; Miyake H; Zellweger T; Chi K; July L; Nelson C; Rennie P
    Urology; 2001 Aug; 58(2 Suppl 1):39-49. PubMed ID: 11502446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
    Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
    Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model.
    Yamanaka K; Gleave M; Muramaki M; Hara I; Miyake H
    Oncol Rep; 2005 May; 13(5):885-90. PubMed ID: 15809754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
    Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
    Leung S; Miyake H; Zellweger T; Tolcher A; Gleave ME
    Int J Cancer; 2001 Mar; 91(6):846-50. PubMed ID: 11275990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.
    Miyake H; Tolcher A; Gleave ME
    Cancer Res; 1999 Aug; 59(16):4030-4. PubMed ID: 10463603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
    Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
    Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.
    Rocchi P; So A; Kojima S; Signaevsky M; Beraldi E; Fazli L; Hurtado-Coll A; Yamanaka K; Gleave M
    Cancer Res; 2004 Sep; 64(18):6595-602. PubMed ID: 15374973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
    Jackson JK; Gleave ME; Yago V; Beraldi E; Hunter WL; Burt HM
    Cancer Res; 2000 Aug; 60(15):4146-51. PubMed ID: 10945622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
    Eder IE; Hoffmann J; Rogatsch H; Schäfer G; Zopf D; Bartsch G; Klocker H
    Cancer Gene Ther; 2002 Feb; 9(2):117-25. PubMed ID: 11857028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
    Gleave ME; Miayake H; Goldie J; Nelson C; Tolcher A
    Urology; 1999 Dec; 54(6A Suppl):36-46. PubMed ID: 10606283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
    Miyake H; Hara I; Gleave ME
    Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen.
    Miyake H; Hara I; Gleave ME; Eto H
    Prostate; 2004 Dec; 61(4):318-23. PubMed ID: 15389725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.